Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660774 · ClinicalTrials.gov registry record
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
A clinical trial of Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 563
- Enrollment target
- 20
- Study locations
NCT03660774: Completed study of Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S.
NCT03660774 is a study of Haemophilia A and Haemophilia B that has completed, run by Novo Nordisk A/S. The registered enrollment target is 563 participants, above the 155-participant average among 8 other Haemophilia A trials with a reported enrollment target (263% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03660774, a study of Haemophilia A and Haemophilia B, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 563 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents. The eTHINK study is designed to understand whether advances in hemophilia treatment have removed any impact of hemophilia. If there still is an impact of hemophilia, the eTHINK study will help to identify which children or adolescents are still at risk, and how to screen other children. Participants and their child will participate in a comprehensive assessment of child's brain development, thinking and behavior through completing tests and questionnaires. There is only one study visit of 1 to 1.5 hours with no follow-up required
Primary Outcome
Normalized score compared to US population (0 = equivalent to US average, negative = below US average, positive = above US average
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (20)
California
- Novo Nordisk Investigational Site - Los Angeles
- Novo Nordisk Investigational Site - Orange
- Novo Nordisk Investigational Site - San Diego
Michigan
- Novo Nordisk Investigational Site - Ann Arbor
- Novo Nordisk Investigational Site - Detroit
Colorado
- Novo Nordisk Investigational Site - Aurora
District of Columbia
- Novo Nordisk Investigational Site - Washington D.C.
Florida
- Novo Nordisk Investigational Site - Tampa
Georgia
- Novo Nordisk Investigational Site - Atlanta
Illinois
- Novo Nordisk Investigational Site - Chicago
Indiana
- Novo Nordisk Investigational Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 563 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2019-10-11 |
What the finished NCT03660774 record still lists
NCT03660774 is an observational study that tracks outcomes without assigning an intervention. The registered 563 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 8 other Haemophilia A trials with a reported enrollment target (263% higher).
The record links to 2 conditions, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT03660774 names 20 study sites across 17 states, led by California, Michigan, Colorado.
Frequently Asked Questions
What is clinical trial NCT03660774 about?
NCT03660774 is a clinical study titled "A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia". The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents. The eTHINK study is designed to understand whether advances in hemophilia treatment have removed any impact of hemophilia...
What is the current status of trial NCT03660774?
This trial is currently completed. The enrollment target is 563 participants. The study started on 2018-09-27. Estimated completion is 2019-10-11.
What conditions does trial NCT03660774 study?
This clinical trial studies the following conditions: Haemophilia A, Haemophilia B.
What interventions are being tested in trial NCT03660774?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT03660774?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03660774 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Haemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03660774's enrollment target sits among peer trials
563 1st of 8 higher than 8 of 8 other Haemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Haemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
RECRUITING · Phase 1
-
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RECRUITING
-
A Research Study Looking at How Food Intake Affects Inno8 in the Body of Healthy People
RECRUITING · Phase 1
-
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
COMPLETED · Phase 3
-
Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI